NGMUSD

Ngm Biopharmaceuticals, Inc.

A biopharmaceutical company in South San Francisco that discovers and develops biology-driven medicines for serious diseases, including candidates aimed at liver, metabolic, and cancer conditions. Founded in 2007 by biotech pioneer Dr. David Goeddel—who was the first scientist hired at Genentech and helped engineer human insulin and growth hormone in bacteria—along with Dr. Jin-Long Chen and Dr. Alex DePaoli. The company went public in 2019 and then returned to private ownership in 2024, when its original backer, The Column Group, took it private again.